Budesonide does not alter the exposure of cabazitaxel in castrate resistant prostate cancer patients.
ID
Bron
Verkorte titel
Aandoening
prostate cancer
cabazitaxel
budesonide
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Evaluation of the interaction of budesonide on the plasma exposure of cabazitaxel.
Achtergrond van het onderzoek
The aim of this study is to study a potential pharmacological interaction between budesonide and cabazitaxel to ensure the safety of concomitantly administrating these 2 agents.
Doel van het onderzoek
Budesonide does not alter the exposure of cabazitaxel in castrate resistant prostate cancer patients.
Onderzoeksopzet
During two courses of cabazitaxel 13 blood samples for pharmacokinetic analysis are drawn to asses the effect of budesonide administration on cabazitaxel plasma exposure.
Onderzoeksproduct en/of interventie
Administration of budesonide during 12 days to asses a possible interaction between cabazitaxel and budesonide. Budesonide will be administered orally 3 times a day 3 mg through entocort capsules. The control group will only receive cabazitaxel.
Algemeen / deelnemers
Anne-Joy M. Graan, de
Rotterdam 3075 EA
The Netherlands
+31 (0)10 7041338
a.degraan@erasmusmc.nl
Wetenschappers
Anne-Joy M. Graan, de
Rotterdam 3075 EA
The Netherlands
+31 (0)10 7041338
a.degraan@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Metastatic castrate resistant prostate cancer (mCRPC) patients with documented disease progression:
A. If measureable: (RECIST v 1.1) progression;
B. If non-measurable: Documented rising PSA levels (at least 2 consecutive rises in PSA over a reference value taken at least 1 week apart) or appearance of new lesions.
2. Previous treatment with a docetaxel-containing regimen;
3. Age ¡Ý 18 years;
4. WHO performance ¡Ý 1;
5. Adequate renal and hepatic functions (serum creatinin < 1.25x upper limit of normal (ULN), total bilirubin < 1.25xULN; alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) < 2.5x ULN, in case of liver metastasis < 5 ULN; alkaline phosphatase (AF) < 5xULN);
6. Adequate hematological blood counts (absolute neutrophil count (ANC) ¡Ý 1.5 x 109/L, platelets ¡Ý 100 x 1012/L);
7. Written informed consent;
8. No chemotherapy within the last 4 weeks before start;
9. No radiotherapy within the last 4 weeks before start;
10. Castration, either surgically or by continued LHRH agonist therapy.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Impossibility or unwillingness to take oral drugs;
2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS-metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
3. Use of medications or dietary supplements known to induce or inhibit CYP3A;
4. Use of other hormonal agents than Gn-RH agonists;
5. Hypersensitiveness to corticosteroids;
6. Systemic or local bacterial, viral, fungal - or yeast infection;
7. Liver cirrhosis;
8. Portal hypertension.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2703 |
| NTR-old | NTR2840 |
| Ander register | METC Erasmus Medical Center : 11-091 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |